Announcing Research 101 | UMR Answers Common Questions About NIH Research in this New Fact Sheet Series
Why Invest in NIH Research? | UMR Offers Fact Sheets Explaining Why Congress Must #keepNIHstrong
Read UMR's Statement on the House Appropriations Committee's Passage of FY23 Labor-HHS Funding Bill
NIH's Role In Sustaining the U.S. Economy | 2022 Update Now Available

A participant in the NIH 2019-2020 Medical Research Scholars Program.

Photo Credit: National Institutes of Health

About This Photo

BioCentury/BIO joint survey finds COVID-19 has forced many companies to modify their clinical trials

COVID-19 is no longer an approaching threat to clinical trials, now the concern for biotechs is how to manage their trials through the crisis. According to a recent survey, on-the-fly protocol amendments are fast becoming a necessity, and companies want assurance regulators will be flexible with the resulting datasets. Over three quarters of the 99 survey respondents said their ability to start new trials or to continue active trials has been hindered by the coronavirus.